• A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer

  NCT07003074

  RecruitingInterventionalPhase 3Updated Jun 25, 2025
• A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

  NCT07043725

  RecruitingInterventionalPhase 3Updated Mar 27, 2026
• Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer

  NCT07008976

  RecruitingInterventionalPhase 3Updated Aug 14, 2025
• A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs

  NCT07483684

  Not yet recruitingInterventionalPhase 3Updated Mar 19, 2026
• The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

  NCT06452706

  RecruitingInterventionalPhase 2Updated Nov 19, 2024
• A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer

  NCT06115902

  CompletedInterventionalPhase 1Updated Jul 8, 2026

ClinicalTrials.gov ID

NCT06561607

Lead Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 3

Enrollment

542Estimated

Last Update Posted

Aug 20, 2024Actual

Start Date

Aug 2024Estimated

Primary Completion Date

Jan 2027Estimated

Completion Date

Dec 2028Estimated

Official Title

A Randomized, Open, Parallel-Controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

Brief Summary

The study is a Phase III, randomized, multicenter, open-label study in HER2-low, HR+ metastatic breast cancer subjects who are patients with locally advanced or metastatic breast cancer with low HER2 expression in the recurrent metastatic stage who have not received chemotherapy. The primary objective of the study is to determine the efficacy and safety of TQB2102 compared to investigator-selected single-agent chemotherapy in the target population. 542 subjects with HER2 immunohistochemistry (IHC )2+/ in situ hybridization (ISH)- and IHC 1+ (HER2-low) expression will be enrolled in 1:1 randomized groups to receive TQB2102 or investigator's choice of single-agent chemotherapy (capecitabine, paclitaxel, or albumin-paclitaxel) until progression of disease (PD), as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1. 1, unless there are unacceptable toxicity, withdrawal of consent, or meeting other discontinuation criteria.

• Breast Cancer

• TQB2102 for Injection
• Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Subjects voluntarily enrolled in this study with good compliance;
• Age: 18-75 years old; Eastern Cooperative Oncology Group Performance Status (ECOG PS) score: 0-1;
• Pathologically confirmed locally advanced or metastatic breast cancer with low HER2 expression and unresectable:
• Defined hormone receptor (HR) status.
• Imaging-confirmed disease progression (during or after completion of the most recent treatment);
• Have at least one measurable lesion according to RECIST 1.1 criteria;
• Good major organ function.

Exclusion Criteria:

• The presence or current concurrent presence of other malignant tumors within 5 years prior to randomization. ;

• Unresolved toxic reactions above Common Terminology Criteria for Adverse Events (CTC AE) grade 1 due to any prior therapy;

• Major surgical treatment, incisional biopsy, or significant traumatic injury within 28 days prior to the start of the pre-randomization period;

• Prolonged unhealed wounds or fractures;

• Previous history of interstitial lung disease/pneumonia requiring steroidal drug intervention;

• The presence of moderate to severe pulmonary dysfunction/disease within 3 months prior to randomization;

• The presence of an arterial/deep vein thrombotic event within 6 months prior to randomization;

• The presence of a medical condition that interferes with intravenous administration, intravenous blood collection, or inability to swallow, chronic diarrhea, intestinal obstruction, or the presence of other factors that interfere with the administration and absorption of medications;

• The presence of grade ≥2 myocardial ischemia or myocardial infarction, cardiac arrhythmias (including QT corrected (QTc) ≥450ms (men) and QTc ≥470ms (women)) and grade ≥2 congestive heart failure (New York Heart Association (NYHA) classification); angina pectoris requiring antianginal medication; and clinically significant heart valve disease;

• Active or uncontrolled ≥ CTC AE grade 2 infection present within 14 days prior to randomization;

• Cirrhosis of the liver, active hepatitis that is not well controlled;

• Renal failure requiring hemodialysis or peritoneal dialysis;

• History of immunodeficiency, including HIV-positive or other acquired or congenital immunodeficiency diseases, or history of organ transplantation;

• Those with routine urinalysis suggestive of urinary protein ≥++ and confirmed 24-hour urine protein quantification >1.0 g;

• Those who have used immunosuppressive or systemic hormone therapy for immunosuppression within 2 weeks prior to randomization;

• Those with a history of psychotropic substance abuse that cannot be abstained from or those with psychiatric disorders;

• Tumor-related symptoms and treatments:

  1. Subjects who have been treated with other antineoplastic agents such as chemotherapy, radical radiotherapy, or immunotherapy within 4 weeks prior to randomization, or who are still within 5 half-lives of the drug (whichever occurs shortest);
  2. Treatment with endocrine therapy, molecularly targeted therapy, or a proprietary Chinese medicine with an anti-tumor indication as specified in the National Medical Products Administration (NMPA) approved drug insert within 2 weeks prior to randomization;
  3. Presence of carcinomatous lymphadenitis, or uncontrollable pleural effusion, ascites, and pericardial effusion of moderate volume or greater that requires repeated drainage to relieve clinical symptoms, or who have received drainage of plasmapheresis for therapeutic purposes within 2 weeks prior to randomization;
  4. Known carcinomatous meningitis or clinically active central nervous system metastases;
  5. Severe bone damage resulting from tumor bone metastases;

• Those who have received a control chemotherapeutic agent of the investigator's choice during the recurrent metastatic phase or for whom a control chemotherapeutic agent of the investigator's choice is inappropriate for reasons such as intolerance or contraindication to that agent;

• Has received prior anti-HER2 therapy;

• Who have developed hypersensitivity to humanized monoclonal antibody products;

• Those who have developed an allergy to any of the study drugs or any component or excipient in the drugs;

• Who have participated in and used another antitumor clinical trial drug within 4 weeks prior to randomization;

• Subjects who, in the judgment of the investigator, have a concomitant disease that seriously jeopardizes the safety of the subject or interferes with the completion of the study, or who are deemed to have other reasons for being unsuitable for enrollment.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY

wuweilwl@163.com13884568149

genhaizhu@163.com13876082272

109024380@qq.com13903246666

fanguguo201@163.com15037272967

ym200678@126.com15713857388

369423971@qq.com18602726300

cong.wang@cttq.com18853118339

Baojilyh_671105251@163.com13008470981